Addiction as a cardiometabolic disease: a neurocardiometabolic framework and the emerging role of GLP-1 receptor therapies.
- DOI
- 10.1093/ehjopen/oeag101
- Published
- 2026 Jul
- Container
- European heart journal open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/ehjopen/oeag101,
title = {Addiction as a cardiometabolic disease: a neurocardiometabolic framework and the emerging role of GLP-1 receptor therapies.},
author = {Seijas-Amigo J and Salgado-Barreira Á and Eiras S and Arias-Rivas S and Rodriguez-Carnero G and Rodriguez-Mañero M and Gonzalez-Juanatey JR},
year = {2026},
journal = {European heart journal open},
doi = {10.1093/ehjopen/oeag101},
url = {https://doi.org/10.1093/ehjopen/oeag101}
}RIS
TY - JOUR TI - Addiction as a cardiometabolic disease: a neurocardiometabolic framework and the emerging role of GLP-1 receptor therapies. AU - Seijas-Amigo J AU - Salgado-Barreira Á AU - Eiras S AU - Arias-Rivas S AU - Rodriguez-Carnero G AU - Rodriguez-Mañero M AU - Gonzalez-Juanatey JR PY - 2026 JO - European heart journal open DO - 10.1093/ehjopen/oeag101 UR - https://doi.org/10.1093/ehjopen/oeag101 ER -
APA
J, S., Á, S., S, E., S, A., G, R., M, R., & JR, G. (2026). Addiction as a cardiometabolic disease: a neurocardiometabolic framework and the emerging role of GLP-1 receptor therapies.. European heart journal open. https://doi.org/10.1093/ehjopen/oeag101
Source records
- pubmed · retrieved 2026-09-25T04:35:44.716Z